Patient characteristics associated with neurotoxicity
| Neurotoxicity grade . | Grade 1-2 . | Grade 3-4 . | Total . | P . |
|---|---|---|---|---|
| Overall, n (%) | 12 (48) | 13 (52) | 25 (100) | |
| Age, y (%) | ||||
| 20-35 | 1 (8.3) | 2 (15.4) | 3 (12) | .963 |
| 36-50 | 1 (8.3) | 2 (15.4) | 3 (12) | |
| 51-65 | 6 (50) | 1 (7.7) | 7 (28) | |
| >65 | 4 (33.3) | 8 (61.5) | 12 (48) | |
| Sex (%) | ||||
| Female | 3 (25) | 6 (46.2) | 9 (36) | .271 |
| Male | 9 (75) | 7 (53.8) | 16 (64) | |
| Pathology (%) | ||||
| DLBCL | 8 (66.7) | 13 (100) | 21 (84) | |
| PMBCL | 1 (8.3) | 0 | 1 (4) | |
| CLL/SCLL | 1 (8.3) | 0 | 1 (4) | |
| ALL | 1 (8.3) | 0 | 1 (4) | |
| HCC | 1 (8.3) | 0 | 1 (4) | |
| Prior therapy (%) | ||||
| R-CHOP | 6 (50) | 8 (61.5) | 14 (56) | |
| R-EPOCH | 4 (33.3) | 5 (38.5) | 9 (36) | |
| R-ICE | 4 (33.3) | 6 (46.2) | 10 (40) | |
| R-DHAP | 3 (25) | 2 (15.4) | 5 (20) | |
| R-GDP | 1 (8.3) | 3 (23.1) | 4 (16) | |
| HD-MTX | 0 | 3 (23.1) | 3 (12) | |
| IT-MTX | 2 (16.7) | 1 (7.7) | 3 (12) | |
| SCT | 3 (25) | 4 (30.8) | 7 (28) | |
| Pretreatment LDH (in lymphoma patients) (%) | ||||
| ≥400 U/L | 5 (50) | 9 (69.2) | 14 (60.9) | .473 |
| <400 U/L | 5 (50) | 4 (30.8) | 9 (39.1) | |
| Cytokine release syndrome (%) | ||||
| 0 | 1 (8.3) | 0 | 1 (4) | .645 |
| 1 | 6 (50) | 5 (38.5) | 11 (44) | |
| 2 | 4 (33.3) | 5 (38.5) | 9 (36) | |
| 3 | 1 (8.3) | 2 (15.4) | 3 (12) | |
| 4 | 0 | 1 (7.7) | 1 (4) | |
| Hematology, ×109/L | ||||
| Platelets | 166.8 ± 36 | 74.6 ± 16 | .030* | |
| WBC | 2.0 ± 1 | 1.9 ± 1 | .852 | |
| ANC | 1.8 ± 1 | 1.8 ± 1 | .494 | |
| Acute-phase proteins at CAR T-cell infusion | ||||
| CRP, mg/L | 102 ± 18 | 110 ± 15 | .733 | |
| Ferritin, ng/mL | 1117 ± 256 | 3428 ± 1078 | .098 |
| Neurotoxicity grade . | Grade 1-2 . | Grade 3-4 . | Total . | P . |
|---|---|---|---|---|
| Overall, n (%) | 12 (48) | 13 (52) | 25 (100) | |
| Age, y (%) | ||||
| 20-35 | 1 (8.3) | 2 (15.4) | 3 (12) | .963 |
| 36-50 | 1 (8.3) | 2 (15.4) | 3 (12) | |
| 51-65 | 6 (50) | 1 (7.7) | 7 (28) | |
| >65 | 4 (33.3) | 8 (61.5) | 12 (48) | |
| Sex (%) | ||||
| Female | 3 (25) | 6 (46.2) | 9 (36) | .271 |
| Male | 9 (75) | 7 (53.8) | 16 (64) | |
| Pathology (%) | ||||
| DLBCL | 8 (66.7) | 13 (100) | 21 (84) | |
| PMBCL | 1 (8.3) | 0 | 1 (4) | |
| CLL/SCLL | 1 (8.3) | 0 | 1 (4) | |
| ALL | 1 (8.3) | 0 | 1 (4) | |
| HCC | 1 (8.3) | 0 | 1 (4) | |
| Prior therapy (%) | ||||
| R-CHOP | 6 (50) | 8 (61.5) | 14 (56) | |
| R-EPOCH | 4 (33.3) | 5 (38.5) | 9 (36) | |
| R-ICE | 4 (33.3) | 6 (46.2) | 10 (40) | |
| R-DHAP | 3 (25) | 2 (15.4) | 5 (20) | |
| R-GDP | 1 (8.3) | 3 (23.1) | 4 (16) | |
| HD-MTX | 0 | 3 (23.1) | 3 (12) | |
| IT-MTX | 2 (16.7) | 1 (7.7) | 3 (12) | |
| SCT | 3 (25) | 4 (30.8) | 7 (28) | |
| Pretreatment LDH (in lymphoma patients) (%) | ||||
| ≥400 U/L | 5 (50) | 9 (69.2) | 14 (60.9) | .473 |
| <400 U/L | 5 (50) | 4 (30.8) | 9 (39.1) | |
| Cytokine release syndrome (%) | ||||
| 0 | 1 (8.3) | 0 | 1 (4) | .645 |
| 1 | 6 (50) | 5 (38.5) | 11 (44) | |
| 2 | 4 (33.3) | 5 (38.5) | 9 (36) | |
| 3 | 1 (8.3) | 2 (15.4) | 3 (12) | |
| 4 | 0 | 1 (7.7) | 1 (4) | |
| Hematology, ×109/L | ||||
| Platelets | 166.8 ± 36 | 74.6 ± 16 | .030* | |
| WBC | 2.0 ± 1 | 1.9 ± 1 | .852 | |
| ANC | 1.8 ± 1 | 1.8 ± 1 | .494 | |
| Acute-phase proteins at CAR T-cell infusion | ||||
| CRP, mg/L | 102 ± 18 | 110 ± 15 | .733 | |
| Ferritin, ng/mL | 1117 ± 256 | 3428 ± 1078 | .098 |
Characteristics are given for patients with grade 1-2 neurotoxicity (n = 12), grade 3-4 neurotoxicity (n = 13), and summarized for all patients (total; n = 25). P values are given for numerical and dichotomous variables. ALL, acute lymphoblastic leukemia; ANC, absolute neutrophil count; CLL/SCLL, chronic lymphocytic leukemia/small cell lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; HCC, hepatocellular carcinoma; HD-MTX, high-dose methotrexate; IT-MTX, intrathecal methotrexate; PMBCL, primary mediastinal large B-cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin;. R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; R-GDP, rituximab, gemcitabine, dexamethasone, cisplatin; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; SCT, stem cell transplantation; WBC, white blood cell.
P ≤ .05.